Trial Profile
A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 05 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Aug 2024.
- 09 Aug 2023 Planned End Date changed from 1 Aug 2025 to 31 Dec 2023.
- 09 Aug 2023 Planned primary completion date changed from 1 Aug 2024 to 31 Aug 2023.